Academic Journal
USTEKINUMAB IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY
| العنوان: | USTEKINUMAB IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY |
|---|---|
| المؤلفون: | Paula Cenira Senger de CASTRO, Daniéla Oliveira MAGRO, Rodrigo Bremer NONES, Thaisa Kowalski FURLAN, Eron Fábio MIRANDA, Paulo Gustavo KOTZE |
| المصدر: | Arquivos de Gastroenterologia (2022) |
| بيانات النشر: | Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Diseases of the digestive system. Gastroenterology |
| مصطلحات موضوعية: | Inflammatory bowel disease, Crohn’s disease, Ustekinumab, Interleukin, Diseases of the digestive system. Gastroenterology, RC799-869 |
| الوصف: | ABSTRACT Background: Real-world data on the use of Ustekinumab (UST) in Brazilian and Latin American patients with Crohn’s disease (CD) are scarce. Objective: The primary endpoint was assessment of clinical remission at weeks 8 and 52, and secondary endpoints were: assessment of clinical response at weeks 8 and 52, endoscopic remission, adverse events, and rates of CD-related abdominal surgery during follow-up. Methods: observational and retrospective study, including patients with CD treated at two centers, who received UST at any time during their treatment. Remission and clinical response were defined as a Harvey-Bradshaw index ≤4 and ≥3 points reduction, respectively. Results: Seventy-four patients were included, 85.1% previously exposed to anti-TNFs. Clinical remission was observed in 45.8% and 59.4% of patients at weeks 8 and 52, respectively. The clinical response rates were 54.2% and 67.6% at weeks 8 and 52. Endoscopic remission was observed in 21.8% of patients. Seventeen patients had adverse events, mostly mild infections, with 22.9% of patients undergoing abdominal surgery (ileocolectomy being the most common procedure). Conclusion UST therapy resulted in significant rates of remission and clinical response, as described in other real-world studies. Few patients had adverse events during treatment, showing its adequate safety profile. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1678-4219 0004-2803 |
| Relation: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032022005001206&lng=en&tlng=en; http://www.scielo.br/pdf/ag/2022nahead/1678-4219-ag-s0004280320220400089.pdf; https://doaj.org/toc/1678-4219 |
| DOI: | 10.1590/s0004-2803.202204000-89 |
| URL الوصول: | https://doaj.org/article/6b948e4be8ae419ea2b646779c7add41 |
| رقم الانضمام: | edsdoj.6b948e4be8ae419ea2b646779c7add41 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 16784219 00042803 |
|---|---|
| DOI: | 10.1590/s0004-2803.202204000-89 |